Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus PROMETHEGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus PROMETHEGAN.
ACUVUE THERAVISION WITH KETOTIFEN vs PROMETHEGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, exerting antihistaminic, sedative, antiemetic, anticholinergic, and local anesthetic effects. Its antiemetic effect is mediated via blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
IV: 25-50 mg every 4-6 hours; IM: 25-50 mg every 4-6 hours; PO: 25-50 mg every 4-6 hours; PR: 25-50 mg every 4-6 hours; Maximum: 300 mg/day.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life: 9-16 hours in adults, with an average of 12 hours. In children, half-life may be shorter (6-9 hours). Clinical context: dosing interval typically every 8-12 hours; accumulation possible with repeated dosing.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal (urinary) as conjugated metabolites; about 70-80% of a dose is excreted in urine within 48 hours. Small amounts appear in feces via biliary elimination (approximately 5-10%).
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine